Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience Inc. has shown significant advancements in its clinical-stage assets, particularly with ALTO-207 (CTC-501), which has demonstrated improved tolerability compared to pramipexole, allowing for higher doses and fast titration that enhance treatment benefits for depressive symptoms. In FY24, the company generated $1.08 billion in revenue, marking an approximate 60% increase from FY23 and indicating strong market demand and growing confidence in its innovative therapies. Additionally, the development of a new transdermal formulation for ALTO-101, which has shown an improved safety profile and favorable pharmacokinetics, further supports the potential for successful outcomes in ongoing clinical trials.

Bears say

Alto Neuroscience Inc has encountered significant challenges, particularly following the failure of its lead asset, ALTO-100, in a pivotal Phase 2b study for major depressive disorder (MDD), which has negatively impacted investor confidence. The company's ongoing clinical programs, including a Phase 2b study in bipolar depression, carry inherent risks and have previously yielded disappointing results, suggesting a low probability of success (POS). Additionally, emerging evidence indicates that deficits in neuroplasticity among patients, including those with cognitive disorders, may exacerbate treatment resistance and hinder therapeutic outcomes, further compounding the company's challenges in developing effective psychiatric treatments.

ANRO has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Buy based on their latest research and market trends.

According to 6 analysts, ANRO has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.